Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 2/2019

01-02-2019 | Original Paper

Identifying Which Place Characteristics are Associated with the Odds of Recent HIV Testing in a Large Sample of People Who Inject Drugs in 19 US Metropolitan Areas

Authors: Barbara Tempalski, Hannah L. F. Cooper, Mary E. Kelley, Sabriya L. Linton, Mary E. Wolfe, Yen-Tyng Chen, Zev Ross, Don C. Des Jarlais, Samuel R. Friedman, Leslie D. Williams, Salaam Semaan, Elizabeth DiNenno, Cyprian Wejnert, Dita Broz, Gabriela Paz-Bailey, for the National HIV Behavioral Surveillance Study Group

Published in: AIDS and Behavior | Issue 2/2019

Login to get access

Abstract

This exploratory analysis investigates relationships of place characteristics to HIV testing among people who inject drugs (PWID). We used CDC’s 2012 National HIV Behavioral Surveillance (NHBS) data among PWID from 19 US metropolitan statistical areas (MSAs); we restricted the analytic sample to PWID self-reporting being HIV negative (N = 7477). Administrative data were analyzed to describe the 1. Sociodemographic Composition; 2. Economic disadvantage; 3. Healthcare Service/Law enforcement; and 4. HIV burden of the ZIP codes, counties, and MSAs where PWID lived. Multilevel models tested associations of place characteristics with HIV testing. Fifty-eight percent of PWID reported past-year testing. MSA-level per capita correctional expenditures were positively associated with recent HIV testing among black PWID, but not white PWID. Higher MSA-level household income and imbalanced sex ratios (more women than men) in the MSA were associated with higher odds of testing. HIV screening for PWID is suboptimal (58%) and needs improvement. Identifying place characteristics associated with testing among PWID can strengthen service allocation and interventions in areas of need to increase access to HIV testing.
Appendix
Available only for authorised users
Footnotes
1
The isolation index measures the extent to which minority members are exposed only to one another, and was calculated per Massey and Denton [32]. The isolation index varies from 0 (no isolation) to 100 (complete isolation).
 
Literature
1.
National Minority AIDS Council. African Americans, health disparities, and HIV/AIDS: recommendations for confronting the epidemic in Black America. Washington, DC: National Minority AIDS Council; 2006.
2.
National Institute on Drug Abuse of the National Institutes of Health. NIH Health Disparities Strategic Plan, Fiscal Years 2009–2013. National Institute on Drug Abuse. Bethesda, MD: NIH; 2009.
3.
National Center for HIV/AIDS VH, STD, and TB Prevention at the Centers for Disease Control and Prevention within the U.S. Department of Health and Human Services. Strategic plan: the division of HIV/AIDS prevention 2011 through 2015. Atlanta, GA: CDC; 2011.
4.
Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17.
5.
Davis CS, Burris S, Kraut-Becher J, Lynch KG, Metzger D. Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health. 2005;95:233–6.CrossRefPubMedPubMedCentral
6.
Heimer R, Grau L, Curtin E, Khoshnood K, Singer M. Assessment of HIV testing of urban injection drug users: implications for expansion of HIV testing and prevention efforts. Am J Public Health. 2007;97:110–6.CrossRefPubMedPubMedCentral
7.
8.
Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Celum CL, et al. Overcoming barriers to HIV testing: preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men. J Acquir Immune Defic Syndr. 2003;32:318–27.CrossRefPubMed
9.
Bowles KE, Clark HA, Tai E, Sullivan PS, Song B, Tsang J, et al. Implementing rapid HIV testing in outreach and community settings: results from an advancing HIV prevention demonstration project conducted in seven U.S. cities. Public Health Rep. 2008;123(Suppl 3):78–85.CrossRefPubMedPubMedCentral
10.
Rhodes T. The ‘risk environment’: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13:85–94. ISSN 0955-3959.
11.
Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201.CrossRefPubMed
12.
Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61:1026–44.CrossRefPubMed
13.
Rhodes T, Wagner K, Strathdee SA, Shannon K, Davidson P, Bourgois P. Structural violence and structural vulnerability within the risk environment: theoretical and methodological perspectives for a social epidemiology of HIV risk among injection drug users and sex workers. In: O’Campo P, Dunn JR, editors. Rethinking social epidemiology: Towards a science of change. New York: Springer; 2012. pp. 205–30.
14.
Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376:268–84.CrossRefPubMedPubMedCentral
15.
16.
17.
Cooper HLF, Bossak B, Tempalski B, Friedman SR, Des Jarlais DC. Geographic approaches to quantifying the risk environment: drug-related law enforcement and access to syringe exchange programmes. Int J Drug Policy. 2009;20:217–26.CrossRefPubMed
18.
Cooper HLF, Bossak B, Tempalski B, Friedman SR, Des Jarlais DC. Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need. J Urban Health. 2009;8:929–45. https://​doi.​org/​10.​1007/​s11524-009-9399-7.CrossRef
19.
Friedman SR, Cooper HLF, Tempalski B, Keem M, Friedman R, Flom PL, et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in U.S.A. metropolitan areas. AIDS. 2006;20:93–9.CrossRefPubMed
20.
Friedman SR, Tempalski B, Brady J, Friedman JJ, Cooper HLF, Flom PL, et al. Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States. Int J Drug Policy. 2007;18:475–85.CrossRefPubMed
21.
Friedman SR, Tempalski B, Brady JE, West BS, Pouget ER, Williams LD, et al. Income inequality, drug-related arrests, and the health of people who inject drugs: reflections on seventeen years of research. Int J Drug Policy. 2016;32:11–6.CrossRefPubMedPubMedCentral
22.
Tempalski B, Flom PL, Friedman SR, Des Jarlais DC, Friedman JJ, McKnight C, et al. Social and political factors predicting the presence of syringe exchange programs in 96 Metropolitan areas in the United States. Am J Public Health. 2007;97:437–47.CrossRefPubMedPubMedCentral
23.
Tempalski B, Cooper H, Friedman SR, Des Jarlais DC, Brady J. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy. 2008;S19:S47–58.CrossRef
24.
Cooper HLF, Des Jarlais DC, Tempalski B, Bossak B, Ross Z, Friedman SR. Drug-related arrest rates and spatial access to syringe exchange programs in New York City health districts: combined effects on the risk of injection-related infections among injectors. Health Place. 2012;18:218–28.CrossRefPubMed
25.
26.
27.
Cooper H, Friedman S, Tempalski B, Friedman R, Keem M. Racial/Ethnic disparities in injection drug use in 94 U.S. metropolitan statistical areas in 1998. Am J Epidemiol. 2005;15:326–34.
28.
Linton SL, Cooper HLF, Kelley ME, Karnes CC, Ross Z, Wolfe ME, et al. HIV infection among people who inject drugs in the United States: geographically explained variance across racial and ethnic groups. Am J Public Health. 2015;105:2457–65.CrossRefPubMedPubMedCentral
29.
30.
Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR. Surveillance Summaries. 2014;63:1–51.
31.
Lansky AA, Abdul-Quader S, et al. Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(Suppl 1):48–55.CrossRefPubMedPubMedCentral
32.
Massey D, Denton N. American Apartheid: segregation and the making of the underclass. Cambridge, Massachusetts: Harvard University Press; 1993.
33.
Henkel D. Unemployment and substance use: a review of the literature 1990–2010. Curr Drug Abuse Rev. 2011;4:4–27.CrossRefPubMed
34.
Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HLF, Hall HI, et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992–2007. PLoS ONE. 2013;8:e64789.CrossRefPubMedPubMedCentral
35.
36.
Salganicoff A, Cubanski J, Ranji U, Neuman T. Health coverage and expenses: impact on older women’s economic well-being. J Women Polit Policy. 2009;30:222–47.CrossRef
37.
Link BG, Phelan JC. Fundamental sources of health inequalities. In: Policy challenges in modern health care. Piscataway, NJ: Rutgers University Press; 2005.
38.
Arnold M, Hsu L, Pipkin S, McFarland W, Rutherford GW. Race, place and AIDS: the role of socioeconomic context on racial disparities in treatment and survival in San Francisco. Soc Sci Med. 2009;69:121–8.CrossRefPubMedPubMedCentral
39.
Cunningham WE, Hays RD, Duan N, Andersen RM, Nakazono TT, Bozzette SA, Shapiro MF. The effect of socioeconomic status on the survival of people receiving care for HIV infection in the United States. J Health Care Poor Underserv. 2005;16:655–76.CrossRef
40.
Joy R, Druyts EF, Brandson EK, Lima VD, Rustad CA, Zhang W, Wood E, Montaner JSG, Hogg RS. Impact of neighborhood-level socioeconomic status on disease progression in a universal health care setting. J Acquir Immune Defic Syndr. 2008;47:500–5.CrossRefPubMed
41.
Nikolopoulos GK, Fotiou A, Kanavou E, et al. National income inequality and declining GDP growth rates are associated with increases in HIV diagnoses among people who inject drugs in Europe: a panel data analysis. PLoS ONE. 2015;10:e0122367.CrossRefPubMedPubMedCentral
42.
Friedman SR, Rossi D, Braine N. Theorizing, “Big Events” as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy. 2009;20:283–91.CrossRefPubMed
43.
Kotranski L, Semaan S, Lauby J, Halbert J, Feighan K. Correlates of HIV seropositivity and HIV testing among out-of-treatment drug users. Am J Drug Alcohol Abuse. 1998;24:377–93.CrossRefPubMed
44.
45.
Blankenship KM, Smoyer AB, Bray SJ, Mattocks K. Black-white disparities in HIV/AIDS: the role of drug policy and the corrections system. J Health Care Poor Underserv. 2005;16:140–56.CrossRef
46.
47.
48.
49.
Seth P, Figueroa A, Wang G, Reid L, Belcher L. HIV testing, HIV positivity, and linkage and referral services in correctional facilities in the United States, 2009–2013. Sex Transm Dis. 2015;42:643–9.CrossRefPubMedPubMedCentral
50.
51.
52.
Dwyer M, Fish DG, Gallucci AV, Walker SJ. HIV Care in Correctional Settings. In: Guide for HIV/AIDS clinical care—2014 Edition. Rockville, MD: U.S. Department of Health and Human Services; 2014.
53.
54.
Pouget ER, Kershaw TS, Niccolai LM, Ickovics JR, Blankenship KM. Associations of sex ratios and male incarceration rates with multiple opposite-sex partners: potential social determinants of HIV/STI transmission. Public Health Rep. 2010;S125:S70–80.CrossRef
55.
Newsome V, Airhihenbuwa CO. Gender ratio imbalance effects on HIV risk behaviors in African American women. Health Promot Pract. 2013;14:459–63.CrossRefPubMed
56.
Paivinen H, Bade S. Voice: challenging the stigma of addiction; a nursing perspective. Int J Drug Policy. 2008;19:214–9.CrossRefPubMed
57.
Denning P. Rethinking the treatment of dual disorders. In: Marlatt A, editor. Harm reduction: pragmatic strategies for managing high risk behaviors. 2d ed. New York: Guilford Press; 2012.
58.
Denning P. Harm reduction therapy with families and friends of people with drug problems. J Clin Psychol. 2010;66:164–74.PubMed
59.
Little J, Franskoviak P. We’re glad you came: harm reduction therapy in community settings. J Clin Psychol. 2010;66:175–88.PubMed
60.
Marlatt GA, Larimer ME, Witkiewitz K, editors. Harm reduction: pragmatic strategies for managing high risk behaviors. New York: Guilford; 2012.
61.
Springer E. Effective AIDS prevention with active drug users: the harm reduction model. J Subst Abuse Treat. 1991;4:141–57.
62.
Shrestha RK, Sansom SL, Kimbrough L, Hutchinson AB, Daltry D, et al. Cost-effectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16:457–64.CrossRefPubMed
63.
64.
65.
Stein R, Green K, Bell K, Toledo CA, Uhl G, et al. Provision of HIV counseling and testing services at five community-based organizations among young men of color who have sex with men. AIDS Behav. 2011;15:743–50.CrossRefPubMed
66.
Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123(Suppl 3):94–100.CrossRefPubMedPubMedCentral
67.
Schwartlander B, Stover J, Hallett T, Atun R, Avila C, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377:2031–41.CrossRefPubMed
68.
Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10:e1001496.CrossRefPubMedPubMedCentral
69.
70.
Cooper HLF, Tempalski B. Integrating place into research on drug use, drug users’ health, and drug policy. Special issue on place matters: drug users’ health and health policy. Guest Ed Int J Drug Policy. 2014;5:333–652.
Metadata
Title
Identifying Which Place Characteristics are Associated with the Odds of Recent HIV Testing in a Large Sample of People Who Inject Drugs in 19 US Metropolitan Areas
Authors
Barbara Tempalski
Hannah L. F. Cooper
Mary E. Kelley
Sabriya L. Linton
Mary E. Wolfe
Yen-Tyng Chen
Zev Ross
Don C. Des Jarlais
Samuel R. Friedman
Leslie D. Williams
Salaam Semaan
Elizabeth DiNenno
Cyprian Wejnert
Dita Broz
Gabriela Paz-Bailey
for the National HIV Behavioral Surveillance Study Group
Publication date
01-02-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2217-z

Other articles of this Issue 2/2019

AIDS and Behavior 2/2019 Go to the issue

Original Paper

Pre-exposure Prophylaxis Among Men Who have Sex with Men: Dual Motivational Model of Intention to Use Pre-exposure Prophylaxis

Original Paper

Who Will Show? Predicting Missed Visits Among Patients in Routine HIV Primary Care in the United States

Original Paper

Men Who Have Sex with Men (MSM) Who Have Not Previously Tested for HIV: Results from the MSM Testing Initiative, United States (2012–2015)

Original Paper

Mind Matters: Treatment Concerns Predict the Emergence of Antiretroviral Therapy Side Effects in People with HIV

Original Paper

“Unspoken Agreements”: Perceived Acceptability of Couples HIV Testing and Counseling (CHTC) Among Cisgender Men with Transgender Women Partners

Original Paper

Comparisons of New HIV Rapid Test Kit Performance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits